Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track BMY with free AI briefings, catalyst countdowns, and dilution alerts.

BMY · BRISTOL MYERS SQUIBB CO

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11.5B Cash on Hand

CF+ Cash Runway

Follow BMY by email Get an email when BMY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BMY, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Oct 2026 · Phase 3 · Recruiting · A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated W
Registry primary completion date, not a results date
Oct 2026 · Phase 3 · Active Trial · A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient
Registry primary completion date, not a results date
Nov 2026 · Phase 3 · Recruiting · A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes i
Registry primary completion date, not a results date
Nov 2026 · Phase 3 · Recruiting · A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes i
Registry primary completion date, not a results date
Nov 2026 · Phase 3 · Recruiting · A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease
Registry primary completion date, not a results date
Nov 2026 · Phase 4 · Recruiting · Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Hea
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Apixaban FDA approved Dec 2012 · Eliquis	Atrial Fibrillation	Phase 3 · NCT05757869	Active not recruiting
Deucravacitinib FDA approved Sep 2022 · Sotyktu	Plaque Psoriasis	Phase 3 · NCT07116967	Recruiting
Xanomeline And Trospium Chloride FDA approved Sep 2024 · Cobenfy	Bipolar Disorder Type I With Mania or Mania With M	Phase 3 · NCT06951711	Recruiting
Nivolumab FDA approved Dec 2014 · Opdivo	Non-small Cell Lung Cancer	Phase 3 · NCT06561386	Recruiting
Ozanimod FDA approved Mar 2020 · Zeposia	Colitis, Ulcerative	Phase 2/3 · NCT05076175	Recruiting
Repotrectinib FDA approved Nov 2023 · Augtyro	Carcinoma, Non-Small-Cell Lung	Phase 3 · NCT06140836	Active not recruiting
Belatacept FDA approved Jun 2011 · Nulojix	Simultaneous Kidney and Pancreas Transplantation	Phase 2 · NCT01790594	Terminated
Ipilimumab FDA approved Mar 2011 · Yervoy	Advanced Renal Cell Carcinoma (RCC)	Phase 1/2 · NCT07293351	Recruiting
Luspatercept FDA approved Nov 2019 · Reblozyl	Myelodysplastic Syndromes (MDS)	N/A · NCT06971185	Completed
Mavacamten FDA approved Apr 2022 · Camzyos	Hypertrophic Cardiomyopathy (HCM)	N/A · NCT06372457	Active not recruiting
PRMT5 Inhibitor BMS-986504	Metastatic Non-small Cell Lung Cancer With MTAP De	Phase 2/3 · NCT07063745	Recruiting
CAPOX	Untreated, Unresectable, or Metastatic Colorectal	Phase 2/3 · NCT07221357	Recruiting
FOLFIRI	Untreated, Unresectable, or Metastatic Colorectal	Phase 2/3 · NCT07221357	Recruiting
FOLFOX	Untreated, Unresectable, or Metastatic Colorectal	Phase 2/3 · NCT07221357	Recruiting
Izalontamab Brengitecan	Non-Small Cell Lung Cancer	Phase 2/3 · NCT07100080	Recruiting
KarX-EC	Alzheimer Disease	Phase 3 · NCT06937229	Recruiting

Also used in these trials (approved or third-party drugs, not BMY's own candidates): Bevacizumab, Carboplatin, Carfilzomib, Cisplatin, Crizotinib, Dexamethasone, Docetaxel Anhydrous, Durvalumab, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Ustekinumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BMY holds $11.5B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Recent financing filings on SEC EDGAR:

Dec 13, 2024 · Shelf registration · S-3ASR

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BMY files for a raise →

Get the full BMY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z